Boston Scientific Corporation (BSX)
| Market Cap | 84.69B |
| Revenue (ttm) | 13.76B |
| Net Income (ttm) | 1.19B |
| Shares Out | 1.46B |
| EPS (ttm) | 0.82 |
| PE Ratio | 70.50 |
| Forward PE | 26.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,656,986 |
| Open | 57.00 |
| Previous Close | 56.28 |
| Day's Range | 56.77 - 58.34 |
| 52-Week Range | 44.35 - 58.34 |
| Beta | 0.78 |
| Analysts | Strong Buy |
| Price Target | 61.32 (+6.07%) |
| Earnings Date | Jan 31, 2024 |
About BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management s... [Read more]
Financial Performance
In 2022, BSX's revenue was $12.68 billion, an increase of 6.68% compared to the previous year's $11.89 billion. Earnings were $642.00 million, a decrease of -34.82%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for BSX stock is "Strong Buy." The 12-month stock price forecast is $61.32, which is an increase of 6.07% from the latest price.
News
Midday Movers: Boston Scientific Heart System, Tesla Cybertruck Accident
U.S. equities were lower at midday on this last trading day of 2023. The Dow, S&P 500, and Nasdaq were down, although all three are likely to end of the year with solid gains.
Boston Scientific Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE™ Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation
MARLBOROUGH, Mass. , Dec. 28, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ Pul...
3 Medical-Device Stocks Could Click in 2024
Baird is bullish on Boston Scientific, Insulet, and DexCom, stocks set to benefit as those companies ramp up sales.
NACD New England honors Waters Corp. and Devoted Health as Public and Private Company “Boards of the Year”
BOSTON--(BUSINESS WIRE)---- $BSX #NACD--NACD New England honors Waters Corp., Devoted Health, David Roux, Ron O'Hanley, and Bob Rivers as 2024 "Directors of the Year" at April 24 Boston gala.
Boston Scientific Closes Acquisition of Relievant Medsystems, Inc.
Recent healthcare plan coverage of Intracept® system expands access to vertebrogenic pain treatment for tens of millions of patients MARLBOROUGH, Mass. , Nov. 17, 2023 /PRNewswire/ -- Boston Scientifi...
What's Next For Boston Scientific Stock After 5% Gains In A Week?
The company reported revenue of $3.5 billion and adjusted earnings of $0.50 per share, compared to the consensus estimates of $3.4 billion and $0.48, respectively.
Boston Scientific to Participate in Stifel's 2023 Healthcare Conference
MARLBOROUGH, Mass. , Nov. 1, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Stifel's 2023 Healthcare Conference on Tuesday, November 14, 2023.
Boston Scientific posts better-than-expected Q3 earnings
Boston Scientific Corp. BSX, -1.90% posted better-than-expected third-quarter earnings early Thursday and raised its full-year guidance. The medical technology company had net income of $505 million, ...
Boston Scientific beats quarterly profit estimates on strength in heart devices unit
Medical device maker Boston Scientific topped Wall Street expectations for third-quarter profit on Thursday, helped by a resilient demand for its heart devices following the post-pandemic rebound in e...
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER 2023
MARLBOROUGH, Mass. , Oct. 26, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.527 billion during the third quarter of 2023, growing 11.2 percent on a reported ...
Boston Scientific AGENT™ Drug-Coated Balloon Demonstrates Superiority to Uncoated Balloon Angioplasty in the AGENT IDE Trial
Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB MARLBOROUGH, Mass. and SAN FRANCISCO , Oct. 25, 2023 /PRNewswire/ -- Bosto...
Boston Scientific may be shielded from weight-loss drugs hit by procedure recovery
Boston Scientific's quarterly results on Thursday are likely to show the benefits of a rebound in elective procedures and help ease fears that the medical device maker could take a hit from the surgin...
REAL-PE Study Demonstrates Statistically Significant Lower Major Bleeding Rates with the EKOS™ Endovascular System Compared to Mechanical Thrombectomy Device for Treatment of Pulmonary Embolism
Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices MARLBOROUGH, Mass. , Oct. 24, 2023 /PRNewswire/ -- Data f...
Should You Pick MGM Resorts Over Boston Scientific Stock For Better Returns?
Given its better prospects, we believe MGM Resorts stock (NYSE: MGM) is a better pick than Boston Scientific stock (NYSE: BSX).
What other industries could weight loss drugs disrupt?
Jared Holz, Mizuho health care sector strategist, joins the ‘Fast Money' traders to discuss Novo Nordisj's kidney trial outcomes and the impact of weight loss drugs on the health care sector.
Dialysis company shares plunge after Ozempic trial success vs. kidney trouble
The trial success of Novo Nordisk's hit drug against kidney failure sent shares of a German kidney dialysis services firm plummeting on Wednesday.
Boston Scientific Announces Conference Call Discussing Third Quarter 2023 Results
MARLBOROUGH, Mass. , Oct. 2, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ...
Stock Plays for October: 3 to Watch, According to J.P. Morgan
The bank has updated its Focus List, the compilation of its analysts' top ideas. These three shares could help a portfolio rebound.
CVS Health appoints Michael F. Mahoney to its Board of Directors
WOONSOCKET, R.I. , Sept. 21, 2023 /PRNewswire/ -- CVS Health Corporation (NYSE: CVS) has appointed Michael F.
6 Growth Stocks That Look Recession-Resistant, According to Morgan Stanley
Apple, Boston Scientific, Costco, Monster Beverage, UnitedHealth, and Colgate-Palmolive shares could still rise in the face of a consumer-spending slump, says Morgan Stanley.
Boston Scientific to acquire Relievant Medsystems for $850 million upfront, plus milestone payments
Boston Scientific Corp. BSX, +0.19% said Tuesday it has entered an agreement to acquire Relievant Medsystems Inc., a privately held medical tech company that has developed a treatment for a form of ch...
Boston Scientific to pay $850 mln upfront to buy Relievant Medsystems
Boston Scientific said on Tuesday it would buy private medical tech company Relievant Medsystems for an upfront cash payment of $850 million.
Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc.
Acquisition intended to expand neuromodulation portfolio to provide more treatment options for people living with chronic low back pain MARLBOROUGH, Mass. , Sept. 19, 2023 /PRNewswire/ -- Boston Scien...
Investors should stick to the ‘late cycle playbook' and buy these sectors, says Morgan Stanley's Mike Wilson
Investors stumped as to where the U.S. economy is situated in the current business cycle, should be focusing on late-cycle stock sectors, which includes one that has been heating up of late.
Is Boston Scientific A Better Pick Over Altria Stock?
We believe that Boston Scientific stock (NYSE: BSX) is a better pick over Altria stock (NYSE: MO), given its better prospects.